Detalles de la búsqueda
1.
Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial.
Lancet
; 387(10027): 1540-1550, 2016 Apr 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-26712084
2.
Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial.
Lancet Oncol
; 17(5): 577-89, 2016 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-27083334
3.
Long-Term Outcomes and Retreatment Among Patients With Previously Treated, Programmed Death-Ligand 1âPositive, Advanced NonâSmall-Cell Lung Cancer in the KEYNOTE-010 Study.
J Clin Oncol
; 38(14): 1580-1590, 2020 05 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-32078391
4.
First-line afatinib vs gefitinib for patients with EGFR mutation-positive NSCLC (LUX-Lung 7): impact of afatinib dose adjustment and analysis of mode of initial progression for patients who continued treatment beyond progression.
J Cancer Res Clin Oncol
; 145(6): 1569-1579, 2019 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-30783814
Resultados
1 -
4
de 4
1
Próxima >
>>